PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization

Infection and Immunity

Volumn 81, Issue 1, 2013, Pages 173-181

  Keller, L E ^a   Jones, C V ^a   Thornton, J A ^b   Sanders, M E ^a   Swiatlo, E ^a   Nahm, M H ^c,d   Park, I H ^c   McDaniel, L S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN K; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL ADHESION; CONTROLLED STUDY; EPITHELIUM CELL; GENE LOCUS; GENETIC COMPLEMENTATION; HOST CELL; HUMAN; HUMAN CELL; MOUSE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTIGENS, SURFACE; BACTERIAL ADHESION; BACTERIAL PROTEINS; CELL LINE; COMPLEMENT C3B; COMPLEMENT FACTOR H; EPITHELIAL CELLS; HUMANS; IMMUNOGLOBULIN A, SECRETORY; MICE; MICE, INBRED C57BL; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84871851813     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00755-12     Document Type: Article

References (66)

1. Gray BM, Converse GM, Dillon HC. 1980. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J. Infect. Dis. 142:923-933.
2. Musher D. 1992. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14: 801-807.
3. Bogaert D, Hermans PWM. 2004. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4:144-154.
4. Avery OT, Dubos R. 1931. The protective action of a specific enzyme against type III pneumococcus infection in mice. J. Exp. Med. 54:73-89.
5. Kim JO, Weiser JN. 1998. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 177:368-377.
6. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
7. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. 2007. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
8. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurl-burt DA, Butler JC, Rudolph K, Parkinson A. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784-1792.
9. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E. 2011. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 8:e1001017. doi:10.1371/journal. pmed.1001017.
10. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. 2005. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116:408-413.
11. SÁ-Leão RNS, Brito-Avô A, Frazão N, Simões AS, Crisóstomo MI, Paulo AC, Saldanha J, Santos-Sanches I, De Lencastre H. 2009. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 15:1002-1007.
12. Park IH, Kim KH, Andrade AL, Briles DE, McDaniel LS, Nahm MH. 2012. Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. mBio 3:e00035-12. doi:10.1128/mBio.00035-12.
13. Hathaway LJ, Meier PS, Bättig P, Aebi S, Mühlemann K. 2004. A homologue of aliB is found in the capsule region of nonencapsulated Streptococcus pneumoniae. J. Bacteriol. 186:3721-3729.
14. Magee AD, Yother J. 2001. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect. Immun. 69:3755-3761.
15. Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. 2007. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect. Immun. 75:83-90.
16. Bergmann S, Hammerschmidt S. 2006. Versatility of pneumococcal surface proteins. Microbiology 152:295-303.
17. Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, Masure HR. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 25:819-829.
18. Salter SJ, Hinds J, Gould KA, Lambertsen L, Hanage WP, Antonio M, Turner P, Hermans PWM, Bootsma HJ, O'Brien KL, Bentley SD. 2012. Variation at the capsule locus, cps, of mistyped and non-typable Streptococcus pneumoniae isolates. Microbiology 158:1560-1569.
19. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EE. 2006. Nontypeable Haemophilus influenzae adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. Infect. Immun. 74:830-838.
20. Johnson RW, McGillivary G, Denoël P, Poolman J, Bakaletz LO. 2011. Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media. Vaccine 29:1211-1221.
21. Xu Q, Kaur R, Casey JR, Sabharwal V, Pelton S, Pichichero ME. 2011. Nontypeable Streptococcus pneumoniae as an otopathogen. Diagn. Micro-biol. Infect. Dis. 69:200-204.
22. Dave S, Carmicle S, Hammerschmidt S, Pangburn MK, McDaniel LS. 2004. Dual roles of PspC, a surface protein of Streptococcus pneumoniae,in binding human secretory IgA and factor H. J. Immunol. 173:471-477.
23. Zhang JR, Mostov KE, Lamm ME, Nanno M, Shimida SI, Ohwaki M, Tuomanen E. 2000. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 102: 827-837.
24. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollings-head SK, Briles DE. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70:2526-2534.
25. Jarva H, Hellwage J, Jokiranta TS, Lehtinen MJ, Zipfel PF, Meri S. 2004. The group B streptococcal Β and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J. Immunol. 172:3111-3118.
26. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Björck L, Meri S. 2002. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J. Immunol. 168:1886-1894.
27. Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GS. 1997. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol. Microbiol. 25:1113-1124.
28. Elm C, Braathen R, Bergmann S, Frank R, Vaerman JP, Kaetzel CS, Chhatwal GS, Johansen FE, Hammerschmidt S. 2004. Ectodomains 3 and 4 of human polymeric immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium. J. Biol. Chem. 279:6296-6304.
29. Hammerschmidt S, Tillig MP, Wolff S, Vaerman JP, Chhatwal GS. 2000. Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol. Microbiol. 36:726-736.
30. Bartilson M, Marra A, Christine J, Asundi JS, Schneider WP, Hromockyj AE. 2001. Differential fluorescence induction reveals Streptococcus pneumoniae loci regulated by competence stimulatory peptide. Mol. Microbiol. 39:126-135.
31. Yother J, McDaniel LS, Briles DE. 1986 Transformation of encapsulated Streptococcus pneumoniae. J. Bacteriol. 168:1463-1465.
32. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. 1991. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect. Immun. 59:222-228.
33. Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, Baxendale HE, Goldblatt F, Botto M, Brown JS. 2008. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect. Immun. 76: 3761-3770.
34. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. 2010. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect. Immun. 78:704-715.
35. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity Proc. Natl. Acad. Sci. U. S. A. 92:11490-11494.
36. Quin LR, Moore QC, McDaniel LS. 2007. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect. Immun. 75:2067-2070.
37. Hammerschmidt S, Agarwal V, Kunert A, Haelbich S, Skerka C, Zipfel PF. 2007. The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J. Immunol. 178:5848-5858.
38. Lu L, Ma Y, Zhang JR. 2006. Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA. J. Biol. Chem. 281: 15464-15474.
39. AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H. 1995. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 59:591-603.
40. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. 1999. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67:4720-4724.
41. Hammerschmidt S. 2006. Adherence molecules of pathogenic pneumococci. Curr. Opin. Microbiol. 9:12-20.
42. Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin WH, McDaniel LS, Eldridge J, Brooks J. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57:1457-1464.
43. Allegrucci M, Sauer K. 2007. Characterization of colony morphology variants isolated from Streptococcus pneumoniae biofilms. J. Bacteriol. 189: 2030-2038.
44. Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala'Aldeen DA, Tuomanen EI. 2009. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J. Clin. Invest. 119:1638-1646.
45. Kaetzel CS. 2005. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev. 206:83-99.
46. Weiser JN, Austrian R, Sreenivasan PK, Masure HR. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62:2582-2589.
47. Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman JP, Lamm ME. 1991. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc. Natl. Acad. Sci. U. S. A. 88:8796-8800.
48. Mestecky J, Russell MW, Elson CO. 1999. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 44:2-5.
49. Phalipon A, Corthesy B. 2007. Novel functions for mucosal SIgA, p 183-202. In Kaetzel CS (ed.), Mucosal immune defense: immunoglobulin A. Springer, New York, NY.
50. Pilette C, Ouadrhiri Y, Godding V, Vaerman JP, Sibille Y. 2001. Lung mucosal immunity: immunoglobulin-A revisited. Eur. Respir. J. 18:571-588.
51. Janoff E, Fasching C, Orenstein J, Rubins J, Opstad N, Dalmasso A. 1999. Killing of Streptococcus pneumoniae by capsular polysaccharidespecific polymeric IgA, complement, and phagocytes. J. Clin. Invest. 104: 1139-1147.
52. Poulsen K, Reinholdt J, Kilian M. 1996. Characterization of the Streptococcus pneumoniae immunoglobulin A1 protease gene (IgA) and its translation product. Infect. Immun. 64:3957-3966.
53. Lipsitch M, Dykes JK, Johnson SE, Ades EW, King J, Briles DE, Carlone GM. 2000. Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine 18:2895-2901.
54. Håvarstein LS, Hakenbeck R, Gaustad P. 1997. Natural competence in the genus Streptococcus: evidence that streptococci can change pherotype by interspecies recombinational exchanges. J. Bacteriol. 179:6589-6594.
55. Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS, Pichon B, Baker S, Parry CM, Lambertsen LM, Shahinas D, Pillai DR, Mitchell TJ, Dougan G, Tomasz A, Klugman KP, Parkhill J, Hanage WP, Bentley SD. 2011. Rapid pneumococcal evolution in response to clinical interventions. Science 331:430-434.
56. Dowson CG, Coffey TJ, Spratt BG. 1994. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. Trends Microbiol. 2:361-366.
57. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6:288-301.
58. Dagan R. 2004. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr. Opin. Otolaryngol. Head Neck Surg. 12:488-494.
59. Fenoll A, Asensio G, Jado I, Berrón SS, Camacho MT, Ortega M, Casal J. 2002. Antimicrobial susceptibility and pneumococcal serotypes. J. Antimicrob. Chemother. 50:13-20.
60. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554.
61. Eskola J, Kilpi T, Palmu A, Jokinen J, Eerola M, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, Lockhart S, Siber G, MäkelÄ PH. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
62. Bluestone CD, Stephenson JS, Martin LM. 1992. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11:7-11.
63. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
64. Onwubiko C, Shires C, Quin LR, Swiatlo E, McDaniel LS. 2007. Characterization of Streptococcus pneumoniae isolated from children with otitis media. FEMS Immunol. Med. Microbiol. 50:119-125.
65. Avery OT, Morgan HJ. 1924. The occurrence of peroxide in cultures of pneumococcus. J. Exp. Med. 39:275-287.
66. Avery OT, MacLeod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J. Exp. Med. 79:137-158.